{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:38Z","timestamp":1792839698324,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhepr.2022.100650","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T12:05:44Z","timestamp":1671192344000},"page":"100650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-3177","authenticated-orcid":false,"given":"Benjamin","family":"Maasoumy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ingiliz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5367","authenticated-orcid":false,"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Stellbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan M.","family":"Schneewei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kahlh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00f6rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"von Karpowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100650_bib1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series\u2606","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a lancet Gastroenterology & Hepatology commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib5","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/infdis\/jiz367","article-title":"Eliminating hepatitis C virus among human immunodeficiency virus-infected men who have sex with men in Berlin: a modeling analysis","volume":"220","author":"Martin","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269977","article-title":"Risk factors for HCV transmission in HIV-positive men who have sex with men in M\u00e9xico","volume":"17","author":"Mata-Mar\u00edn","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100650_bib7","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","article-title":"Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression","volume":"9","author":"Hosseini-Hooshyar","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jhepr.2022.100650_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/cix1007","article-title":"Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100650_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100650_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640619835394","article-title":"High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients","volume":"7","author":"Chromy","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2022.100650_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection","volume":"75","author":"Matthews","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 Weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100650_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","article-title":"Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial","volume":"4","author":"Boerekamps","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/ciy913","article-title":"Ledipasvir\/sofosbuvir for 8 Weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals","volume":"69","author":"Naggie","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib19","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MCG.0000000000000076","article-title":"Distinct features in natural history and outcomes of acute hepatitis C","volume":"49","author":"Bunchorntavakul","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100650_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100650_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/v14030614","article-title":"Four weeks treatment with glecaprevir\/pibrentasvir\u00a0+ ribavirin-A randomized controlled clinical trial","volume":"14","author":"Madsen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2022.100650_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100650_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100650_bib25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1126\/science.abc1076","article-title":"Ethics of controlled human infection to address COVID-19","volume":"368","author":"Shah","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2022.100650_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2022.100650_bib27","doi-asserted-by":"crossref","first-page":"e4260","DOI":"10.1093\/cid\/ciaa1725","article-title":"Safety and efficacy of CR6261 in an Influenza A H1N1 healthy human challenge model","volume":"73","author":"Han","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100650_bib28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","article-title":"Controlled human infection model \u2014 fast track to HCV vaccine?","volume":"385","author":"Liang","year":"2021","journal-title":"New Engl J Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:30:45Z","timestamp":1762900245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2589555922002221"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100650","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100650"}}